Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

33 Comparative Safety and Tolerability of Nefazodone. David L. Dunner, M.D., and Lyle K. Laird, Pharm.D., B.C.P.P. From the Department of Psychiatry and Behavioral Sciences, University of Washington, and the Center for Anxiety and Depression, Seattle (Dr. Dunner); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, and the School of Pharmacy, University of Colorado Health Sciences Center, Denver (Dr. Laird). Reprint requests to: David L. Dunner, M.D., Department of Psychiatry and Behavioral Sciences, University of Washington, Center for Anxiety and Depression, 4225 Roosevelt Way, N.E., Suite 306C, Seattle, WA 98105-6099 (e-mail: [email protected]). 36 Nefazodone: Discontinuation Issues and Safety in Chronic Major Depression. John Zajecka, M.D., and LaGenia Bailey, Pharm.D. From the Department of Psychiatry, Rush-Presbyterian-St. Luke’s Medical Center (Dr. Zajecka), and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company (Dr. Bailey), Chicago, Ill. Reprint requests to: John Zajecka, M.D., Department of Psychiatry, Rush-Presbyterian-St. Luke’s Medical Center, 1725 West Harrison St., Ste. 955, Chicago, IL 60612 (e-mail: [email protected]). 38 Effects of Nefazodone on Body Weight. Norman Sussman, M.D., and Julia L. Seabolt, Pharm.D. From the Department of Psychiatry, New York University School of Medicine (Dr. Sussman), and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company (Dr. Seabolt), New York. Reprint requests to: Norman Sussman, M.D., Department of Psychiatry, New York University School of Medicine, 150 E. 58th St., 27th Floor, New York, NY 10155 (e-mail: [email protected]).